Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« AI and IoT Among Disruptive Enterprise Technologies to Watch

Hyaluronidase treatment of high HA pancreatic cancer increased progression-free survival »

Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device

July 3, 2016 by 2012pharmaceutical

Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device

Author: David Orchard-Webb, PhD

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 1,093 other subscribers
Recent Posts
- Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
- Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
- Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
- The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
- Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
- Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation October 4, 2022
- 2022 Albert Lasker Basic Medical Research Award for Integrins—Mediators of Cell-Matrix and Cell-Cell Adhesion September 28, 2022
- Clarivate Analytics – a Powerhouse in IP assets and in Pharmaceuticals Informercials September 15, 2022
- Near Term Investment Outlook for 2023: A Perspective from Advisors Potentially Affecting M&A Landscape August 5, 2022
- SOP for production of WordClouds for articles in the NEW GENRE Audio English-Spanish: BioMed e-Series – 18 Volumes in Medicine July 25, 2022
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: